z-logo
Premium
Decreased Serum Linezolid Levels in a Critically Ill Patient Receiving Concomitant Linezolid and Rifampin
Author(s) -
Gebhart Benjamin C.,
Barker Brian C.,
Markewitz Boaz A.
Publication year - 2007
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.27.3.476
Subject(s) - linezolid , medicine , concomitant , antibiotics , staphylococcus aureus , intensive care medicine , drug , drug resistance , pharmacology , microbiology and biotechnology , vancomycin , biology , bacteria , genetics
Serious gram‐positive infections present an increasingly common therapeutic dilemma. Combination antimicrobial regimens (e. g., linezolid with rifampin) aimed at improving bacterial eradication and preventing resistance are often used; however, most data supporting this treatment strategy are not from randomized controlled trials. We describe a patient with disseminated community‐acquired methicillin‐resistant Staphylococcus aureus infection who experienced a possible drug interaction between linezolid and rifampin that resulted in decreased serum linezolid levels. To our knowledge, this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin. Although we hypothesize that the reaction was caused by P‐glycoprotein expression, further study is warranted.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here